Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Prothena Corporation plc
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
April 15, 2024
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena to Participate in Upcoming Healthcare Conferences
March 05, 2024
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena Appoints David Ford to Newly Created Chief People Officer Position
March 04, 2024
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate
February 21, 2024
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights
February 15, 2024
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024
February 08, 2024
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs
January 08, 2024
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena Reports Third Quarter 2023 Financial Results and Business Highlights
November 02, 2023
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena to Report Third Quarter 2023 Financial Results on November 2
October 26, 2023
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena to Participate in Upcoming Healthcare Conferences
August 31, 2023
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena Reports Second Quarter 2023 Financial Results and Business Highlights
August 03, 2023
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena to Report Second Quarter 2023 Financial Results on August 3
July 27, 2023
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena Presents New Research in the Treatment of Alzheimer’s Disease at Alzheimer’s Association International Conference® 2023 (AAIC®)
July 17, 2023
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena to Present New Data from Alzheimer’s Disease Programs at Alzheimer’s Association International Conference® 2023 (AAIC®)
July 11, 2023
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody
July 10, 2023
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with Birtamimab
June 27, 2023
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena to Participate in Jefferies 2023 Healthcare Conference
June 02, 2023
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors
May 16, 2023
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena Reports First Quarter 2023 Financial Results and Business Highlights
May 04, 2023
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena to Report First Quarter 2023 Financial Results on May 4
April 27, 2023
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena to Participate in 2023 Bank of America Healthcare Conference
April 24, 2023
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023
March 31, 2023
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena to Participate in Stifel 2023 Virtual CNS Days
March 21, 2023
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena to Highlight Next Generation Treatments for Alzheimer’s and Parkinson’s Disease at the AD/PD 2023 Meeting
March 14, 2023
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights
February 23, 2023
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
February 16, 2023
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 03, 2023
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease
January 31, 2023
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares
December 14, 2022
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Prothena Announces Proposed Public Offering of Ordinary Shares
December 13, 2022
From
Prothena Corporation plc
Via
Business Wire
Tickers
PRTA
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.